Toward optimizing outcomes in Her2-positive gastric cancer: timing and genomic context matter

Ann Oncol. 2018 Apr 1;29(4):801-802. doi: 10.1093/annonc/mdy066.

Authors

S J Klempner¹, J Chao²

Affiliations

¹ The Angeles Clinic and Research Institute, Los Angeles, USA; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA. Electronic address: [email protected].
² Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, USA.

PMID: 29462252
DOI: 10.1093/annonc/mdy066

No abstract available

Publication types

Editorial
Comment

MeSH terms

Genomics
Humans
Lapatinib
Receptor, ErbB-2
Stomach Neoplasms*
Treatment Outcome

Substances

Lapatinib
Receptor, ErbB-2